GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
W

West Pharmaceutical Services WST · USD

Health Care · Health Care Equipment & Supplies · US listing · 🇺🇸 United States

S&P 500

Compare

413.09

+3.32%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Analyst ratings

21 analysts, 1 Nov 2026. The analysts' own views, not ours.

  • 7Strong buy
  • 13Buy
  • 1Hold
  • 0Sell
  • 0Strong sell

Price targets

Brokers' own targets, 1 Nov 2026. Not our view.

Last close 413.09Average target 405.40

Low
365.00
Average
405.40
Median
400.00
High
447.00

Forecasts

Analyst averages for the fiscal years ahead

FY2026FY2027FY2028FY2029FY2030
Revenue$3.42bn$3.61bn$3.89bn$4.19bn$4.41bn
Revenue, highest$3.43bn$3.64bn$4.01bn$4.25bn$4.47bn
Revenue, lowest$3.35bn$3.55bn$3.71bn$4.11bn$4.33bn
Earnings per share9.4110.2411.7713.3714.45
Earnings per share, highest9.6310.7612.9213.6214.72
Earnings per share, lowest9.009.4710.6813.0414.09
Analysts9111155

Earnings against forecasts

Earnings per share by fiscal quarter

Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024
Forecast2.202.081.691.851.701.521.251.74
Reported2.662.372.132.041.961.841.451.82
Difference+20.9%+13.9%+25.8%+10.2%+15.4%+20.7%+16.4%+4.8%

Rating changes

Latest broker notes

  • CitigroupBuy
  • Evercore ISI GroupOutperform
  • Morgan StanleyEqual Weight
  • Evercore ISI GroupOutperform
  • KeybancOverweight
  • BarclaysEqual Weight → Overweight
  • Stephens & Co.Overweight
  • Morgan StanleyEqual Weight
  • BarclaysEqual Weight
  • BarclaysEqual Weight
  • BarclaysEqual Weight
  • Evercore ISI GroupOutperform

Quality and value scores

Models run by our data supplier, not our view and not investment advice

Model

Quality score

8 / 10

Revenue growth 8.2% a year over 10 years. Return on equity 15.5%.

Model fair value

293.55

From earnings 293.55, from revenue 264.63.

Piotroski score

3 / 9

A nine-point test of financial strength, for 31 Dec 2025.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.